CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 1995; 45:199
doi: 10.3322/canjclin.45.4.199
© 1995 American Cancer Society
This Article
Right arrow Full Text (PDF) Freely available
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hortobagyi, G. N.
Right arrow Articles by Buzdar, A. U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hortobagyi, G. N.
Right arrow Articles by Buzdar, A. U.

CA: A Cancer Journal for Clinicians, Vol 45, Issue 4 199-226, Copyright © 1995 by American Cancer Society

ARTICLES

Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy

G. N. Hortobagyi and A. U. Buzdar
Department of Breast and Gynecologic Medical Oncology, University of Texas M.D. Anderson Center in Houston, USA.

Results from studies of adjuvant systemic therapy for primary breast cancer accumulated over the past 20 years have clearly established that this treatment approach improves disease-free and overall survival rates in high-risk patients. As a result, adjuvant systemic therapy has become an integral component of the modern, multimodality approach to management of primary breast cancer. However, controversies about the most effective approaches remain, and research continues. This article reviews the current status of adjuvant systemic therapy for primary breast cancer and discusses areas of persistent controversy.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
C. Botti, S. Buglioni, M. Benevolo, D. Giannarelli, P. Papaldo, F. Cognetti, P. Vici, F. Di Filippo, F. Del Nonno, F. M. Venanzi, et al.
Altered Expression of FAS System Is Related to Adverse Clinical Outcome in Stage I-II Breast Cancer Patients Treated with Adjuvant Anthracycline-Based Chemotherapy
Clin. Cancer Res., February 15, 2004; 10(4): 1360 - 1365.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. L. Aft, J. S. Lewis, F. Zhang, J. Kim, and M. J. Welch
Enhancing Targeted Radiotherapy by Copper(II)diacetyl- bis(N4-methylthiosemicarbazone) Using 2-Deoxy-D-Glucose
Cancer Res., September 1, 2003; 63(17): 5496 - 5504.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Gutman, S. Couillard, F. Labrie, B. Candas, and C. Labrie
Effects of the Antiestrogen EM-800 (SCH 57050) and Cyclophosphamide Alone and in Combination on Growth of Human ZR-75-1 Breast Cancer Xenografts in Nude Mice
Cancer Res., October 1, 1999; 59(20): 5176 - 5180.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. N. Hortobagyi
Treatment of Breast Cancer
N. Engl. J. Med., October 1, 1998; 339(14): 974 - 984.
[Full Text] [PDF]

Home page
 The OncologistHome page
F. J. Esteva and G. N. Hortobagyi
Integration of Systemic Chemotherapy in the Management of Primary Breast Cancer
Oncologist, October 1, 1998; 3(5): 300 - 313.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by American Cancer Society.